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DOI: 10.1039/c002411bTetranuclear cationic open boxes non-covalently bind DNA major
groove. By contrast, they covalently bind cysteine after ligand
exchange reactions. In addition, these systems exhibit potent anti-
tumour activity circumventing cisplatin resistance.Introduction
In recent years, the self assembly process between transition metal
ions and organic linkers to give discrete supramolecular boxes has
been widely investigated. The versatility of these molecular cages has
been exploited to generate confined cavities in which selective
molecular recognition processes take place,1 leading to applications
ranging from sensing,2 stabilisation of reactive species3 to vectors for
drug delivery.4 Traditionally, metal fragments providing 90 coordi-
nation geometries in combination with linear organic spacers have
been used to form square and rectangular architectures.5 Recently,
metal complexes with octahedral geometry have been employed as
building blocks for the construction of novel supramolecular boxes
with different properties.6 For this purpose, blocking chelating
ligands are necessary to control the accessibility to the coordination
sites of the octahedral metal centre in order to favour the formation
of cyclic polynuclear systems. In this regard, arene ruthenium
complexes (arene¼ benzene, toluene, p-cymene, hexamethylbenzene)
have been extensively used to generate supramolecular assemblies.7–9
On the other hand, a large number of compounds containing
metals other than platinum10 have been investigated in the search for
anticancer agents overcoming the high toxicity and spontaneous or
acquired resistance to Pt-based drugs.11 It should be highlighted that
the improvement of the activity of these metal anticancer compounds
lies in the fine-tuning of their biological activity and mechanism of
action by the appropriate choice of the metal, its oxidation state and
of the ligands.12,13 In this context, ruthenium compounds and, in
particular, ruthenium-arene organometallic complexes have recentlyaDepartamento de Quımica Inorganica, Universidad de Granada, Av.
Fuentenueva S/N, 18071 Granada, Spain. E-mail: ebaream@ugr.es;
jarn@ugr.es; Fax: +34 958 248526; Tel: +34 958 248093
bSchool of Chemistry, Newcastle University, Bedson Building, Newcastle
Upon Tyne, UK NE1 7RU
† Electronic supplementary information (ESI) available: Detailed
experimental methods, elemental analysis and 1H NMR spectra of 2a–c
complexes, UV-vis, CD and fluorescence spectra exhibiting the
interaction of 1a, 1c, 2a and 2c with ct-DNA and 1H NMR spectra
showing the interaction of 2a–c with cysteine. CCDC reference number
764877. For ESI and crystallographic data in CIF or other electronic
format see DOI: 10.1039/c002411b
‡ Rotation freedom about the Ru-(phen) make it possible the cyclic
system to adopt additional conformations.
This journal is ª The Royal Society of Chemistry 2010shown a high potential for the development of metal-based anti-
cancer drugs10,14 as they exhibit interesting features, such us robust-
ness, low toxicity and combine a good balance of hydrophilicity and
hydrophobicity, which is a key issue for their transport in biological
media.4 In this regard, we have previously reported on the formation
of a series of robust half-sandwich Ru(II) assemblies able to give non-
covalent interactions with DNA and exhibiting a selective cytotoxic
activity towards ovarian A2780R cancer cell lines with acquired
resistance to cisplatin.9
Moreover, the cathepsin B enzyme activity inhibition exhibited by
some Ru and Pd compounds, related to their binding to the cysteine
residues of the enzyme active site, also correlates with their enhanced
cytotoxicity.15 In addition, it has been shown that certain types of
tumour cells expose unusually high levels of negatively charged
phospholipids at their surface.16 Finally, it has also been proven that
the incorporation of a redox active functionality on an antitumour
drug increases its toxicity towards tumour cells.17
Taking into account the above considerations, our group is
interested in the design of novel cationic metallacycles using Ru-p-
cymene building blocks connected through organic spacers of
different lengths and shapes and incorporating a redox function in
order to investigate the possible synergistic effect of this additional
feature in the citotoxic properties of these systems.
In this communication, we report that the arene ruthenium dinu-
clear systems [(Cy)2Ru2(m-OO,O
0O0-L)Cl2] (Cy: p-cymene; phen:
4,7-phenanthroline; 1a: 1,4-benzoquinone-2,5-diolato (dhbq); 1b:
2,5-dichloro-p-benzoquinone-3,6-diolato (chloranilato); 1c:
1,4-naphtoquinone-5,8-diolato (dhnq)) can be employed to build
metallarectangles of the general formula [(Cy)4Ru4(m-OO,O
0O0-L)2-
(m-phen)2](CF3SO3)4 (2a–c) (Scheme 1). These compounds have been
structurally characterised and their electrochemical behaviour,Scheme 1 Reaction of formation of the [(Cy)4Ru4(m-OO,O
0O0-L)2-
(m-phen)2](CF3SO3)4 (2a–c) cyclic assemblies.
CrystEngComm, 2010, 12, 2343–2346 | 2343
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View Onlinereactivity towards bio-relevant species and in vitro anticancer activity
have been studied in order to establish if there is a relation among
their structural features, robustness, redox activity and cytotoxicity.Results and discussion
Synthesis and characterization of the cyclic assemblies
The dinuclear complexes [(Cy)2Ru2(m-OO,O
0O0-L)Cl2] (1a: 1,4-ben-
zoquinone-2,5-diolato (dhbq); 1b: 2,5-dichloro-p-benzoquinone-3,6-
diolato (chloranilato); 1c: 1,4-naftoquinone-5,8-diolato (dhnq)) have
been obtained following literature methods.9,18 Removal of the
chloride ligands of 1a–c by treatment with AgCF3SO3 leads to the
formation of the corresponding [(Cy)4Ru4(m-OO,O
0O0-L)2-
(CF3SO3)2] species (1
0a–c), which upon posterior reaction with the
N,N0-donor 4,7-phenanthroline bent spacer yields the tetranuclear
metallacycles [(Cy)4Ru4(m-OO,O
0O0-L)2(m-phen)2](CF3SO3)4 (phen:
4,7-phenanthroline; 2a: dhbq; 2b: chloranilato; 2c: dhnq). These tet-
ranuclear systems have been studied by 1H NMR spectroscopy and
the X-ray crystal structure of 2a has been determined. 1H NMR
spectra for 2a–c in both DMSO-d6 and D2O remain unaltered at least
for two weeks, which is indicative of the robustness of these species in
both solvents.
The single-crystal X-ray diffraction analysis showed that
compound 2a crystallizes in the P21 space group and is composed of
rectangular tetranuclear [(Cy)4Ru4(dhbq)2(phen)2]
4+ cationic open
boxes (Fig. 1) of approximate dimensions 8.0  15.0  17.0 A. The
ruthenium metal centres, coordinated to one p-cymene ring, are
bridged by the dianionic 1,4-benzoquinone-2,5-diolato ligands and
the neutral N,N0-phen linkers, which show OO,O0O0-exotetradentate
and N4,N7-exobidentate coordination modes, respectively. The open
box adopts a cone conformation, thereby creating a vase-like cavity
suitable for molecular recognition processes. Indeed, the wider
entrance of the cone hosts one non-coordinated 4,7-phen molecule,
whose shortest atom-atom contacts with the 1,4-benzoquinone-2,5-
diolato and 4,7-phen ligands situated in the cavity walls are 3.18 and
3.39 A, respectively. The tetranuclear coordination rectangles stack
along the b-axis to build supramolecular zig-zag chains supported by
p–p interactions established between the p-cymene moieties of
adjacent assemblies (ESI, Fig. S1).† The presence of hosted phen
moieties inside the cavities is also supported by elemental analysis andFig. 1 Crystal structure of the supramolecular assembly [(Cy)2Ru4(1,4-
benzoquinone-2,5-diolato)2(phen)2]
4+ (2a). C (grey), N (blue), O (red), Ru
(orange). H-atoms have been omitted for clarity.
2344 | CrystEngComm, 2010, 12, 2343–23461H NMR spectroscopy (see supporting information). It should be
noted that for 2c, the elemental analysis and 1H NMR integrals
account for four phen molecules encapsulated in the metallarectangle
cage. This fact should be related to the lengthened dimensions and
extended aromaticity of the 1,4-naphtoquinone-5,8-diolato bridges
and a probable trans disposition of the 4,7-phen moieties which
permit to host two pairs of stacked phen moieties above and below
the Ru4 plane.Reactivity and host–guest chemistry of the Ru(II) assemblies
towards bio-relevant species
The study of the interaction of these systems with DNA and their
possible significant effects on DNA structure is of great importance
as DNA is thought to be the primary cellular target for Ru(II)
complexes,19,13 as for many metal-based anticancer drugs. To gain
additional insight into the potential modes of interaction, we have
studied the binding of the dinuclear and tetranuclear complexes to
adenosine monophosphate (AMP) as a model of DNA, by means of
1H NMR spectroscopy in aqueous solution at pH 7.0. The experi-
ments show that the chloride ligands in 1a–c exchange with the
mononucleotide within two hours, which is in agreement with related
mononuclear [(Cy)RuLCl] systems.13 Indeed, in the case of the
dinuclear 1a and 1c species, the addition of AMP is responsible for an
important upfield shift (0.4 ppm) of the signals of the aromatic
protons of benzoquinone and naphtoquinone units. On the other
hand, only a slight upfield shift of the 1H NMR signals is observed
upon addition of AMP to solutions of 2a–c, indicating the robustness
of the assemblies and that the interaction of the mononucleotide
takes probably place at the external surface of the cage through p–p,
anion-p and electrostatic interactions. This result is expected as the
p–p stacking between the free phen included inside the cavity and the
phen ligands situated in the walls is very strong (in the case of 2a, is
close to ideal, with interplanar distances and dihedral angles of
3.82–4.02 A and 5.20–6.31) avoiding a possible exchange and, as
a consequence, the incorporation of the AMP inside the receptor.
On the other hand, the ability of 1a, 2a, 1c and 2c to interact with
calf-thymus ct-DNA has been examined by means of biophysical
methods (UV-vis, circular dichroism (CD) and competitive binding
essays with ethidium bromide (EB)) (Fig. 2, ESI Fig. S3, S4 and S5).†
Of particular interest are the EB competitive studies, which show that
the strength of the interaction follows the trend 1a < 1c  2c < 2a.
This trend is further confirmed by the CD measurements showing the
largest ellipticity diminution for the 2a system, which might be related
to a probable DNA coiling induced by the supramolecular binding of
2a to the DNA major groove in a similar way to Hannon’s metal-
lacylinders (Fig. 2).20 The ability of 2a to interact with DNA and to
induce conformational changes is a probable result of a mixture of
electrostatic interactions with polyanionic DNA and size and shape
complementarity of this system with the DNA major groove.
Finally, reactions with sulfur containing biomolecules (i.e. amino
acids, proteins) appear to play an important role in the biological
chemistry of soft metal based metallodrugs, as such interactions can
be responsible for drug inactivation/activation processes and/or the
drug delivery mechanism.13,15 Taking it into account, we have studied
the interaction of 1a–c and 2a–c systems with the S-donor amino acid
L-cysteine. Indeed, 1H NMR studies show that incubation of 1a–c
and 2a–c with 4 equiv. of cysteine at 37 C and at pH 7.4, leads toThis journal is ª The Royal Society of Chemistry 2010
Fig. 2 (a) CD spectra of the titration of ct-DNA (150 mM) with
[(Cy)2Ru4(1,4-benzoquinone-2,5-diolato)2(phen)2](CF3SO3)4 (2a). (b)
Competitive binding assays: fluorescence spectra of intercalated ethidium
bromide (5 mM) in DNA (4 mM) upon addition of increasing amounts of
2a in 1mM sodium cacodylate buffer and 20 mM NaCl.
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View Onlinerapid ligand exchange reactions of chloride and phen ligands for 1a–c
and 2a–c sets of compounds (ESI, Fig. S6).†Redox properties
Compounds 1a–c and 2a–c have been studied by cyclic voltammetry.
The redox response of the dinuclear 1a–b species has been previously
described by Therrien et al.8 It should be noted that 1c behaves in
a similar way displaying two reversible reduction peaks at0.85 and
1.9 V. Like in the case of the dinuclear compounds, the
response of the tetraruthenium complexes 2a–b is analogous to
their related metallacycles [(Cy)4Ru4(dhbq)2(bpy)2](CF3SO3)4 andTable 1 IC50
a values (in mM) in ovarian A2780 and cisplatin resistant A2780
cisplatin sensitive)
Compound A2780c
[(Cy)4Ru4(Hoxonato)2(bpy)2] (CF3SO3)4 19
[(Cy)4Ru4(Hoxonato)2(phen)2] (CF3SO3)4 15
[(Cy)2Ru2(dhbq)Cl2] (1a) 9.5
[(Cy)2Ru2(chloranilato)Cl2] (1b) Inactive
[(Cy)2Ru2(dhnq)Cl2] (1c) 0.95
[(Cy)4Ru4(dhbq)2(phen)2](CF3SO3)4 (2a) 0.79
[(Cy)4Ru4(dhbq)2(bpy)2](CF3SO3)4 66
[(Cy)4Ru4(chloranilato)2(phen)2](CF3SO3)4 (2b) 3.30
[(Cy)4Ru4(chloranilato)2(bpy)2](CF3SO3)4 43
[(Cy)4Ru4(dhnq)2(phen)2](CF3SO3)4 (2c) 0.20
Phen 50
Cisplatin 0.69
a IC50: drug concentration necessary for 50% inhibition of cell viability.
b T
dichloro-3,6-dihydroxy-p-benzoquinone; H2dhnq¼ 5,8-dihydroxy-1,4-naftoq
This journal is ª The Royal Society of Chemistry 2010[(Cy)4Ru4(chloranilato)2(bpy)2](CF3SO3)4
8 and only a slight shift of
the waves to less negative potentials (< 0.1 V) is observed. Note-
worthy, the 2c system shows three reductions peaks at 0.72, 0.90
and 2.0 V. The first two events are indicative of electronic
communication being transmitted through the phen bridges leading
to consecutive reduction processes of one dhnq side after the other.
This unusual feature is probably related to the extended aromaticity
of the phen ligand, which put this system in close relation to the
classical pyrazine bridged Creutz-Taube dinuclear Ru systems.21
It should be noted, however, that the redox activity in our case is
ligand centred.Cytotoxicity studies
Table 1 summarises the antiproliferative activity results of the dinu-
clear 1a–c and the tetranuclear 2a–c species as well as related arene
Ru(II) tetranuclear assemblies against the cisplatin sensitive A2780
and cisplatin resistant A2780R ovarian cancer cell lines.
In the case of the A2780 cell line, we have observed that 1b is
inactive whereas 1a, 2b, and the previously reported [(Cy)4Ru4-
(Hoxonato)2(phen)2](CF3SO3)4, [(Cy)4Ru4(Hoxonato)2(bpy)2]-
(CF3SO3)4
9 show moderate activities, in the range of one to two
orders of magnitude lower than those exhibited by cisplatin
(Table 1). Nevertheless, 2b is almost thirteen times more
potent as an inhibitor than the [(Cy)4Ru4(chloranilato)2-
(bpy)2](CF3SO3)4 related tetramer reported by Therrien et al.
8 It
is worth noting that the dinuclear 1c and tetranuclear 2c species
posses a potent activity, with IC50 values of 0.95 and 0.20,
respectively. In addition, the cyclic 2a species, with an IC50 value
of 0.79, can be considered equipotent to cisplatin and clearly
overcomes the performance of the related [(Cy)4Ru4(dhbq)2-
(bpy)2](CF3SO3)4 system (Table 1).
8 According with these
results, the activity of the dinuclear systems is clearly out-
performed by the tetranuclear ones. Particularly, 2c shows the
best performance with an activity ca. 4 times higher than that of
cisplatin in this cancer cell line.
Regarding the behaviour of these systems against A2780R
cancer cell line with acquired resistance to cisplatin, the cytotoxic
effect of 1a and 1b is relatively low. However, 1c, 2a–c proved to be
more active against human ovarian A2780R cancer cells than
cisplatin and the [(Cy)4Ru4(Hoxonato)2(phen)2](CF3SO3)4 andR cancer cell lines and resistance factor RF (IC50 cisplatin resistant/IC50
A2780Rc RF Ref.
4.6 0.2 9
8.3 0.6 9
24 2.5 b
Inactive — b
1.09 1.1 b
2.40 3.0 b
— — 8
3.20 1.0 b
— — 8
0.18 0.9 b
Inactive — b
4.00 5.6 b
his work. H2dhbq¼ 2,5-dihydroxy-1,4-benzoquinone; chloranilic¼ 2,5-
uinone. c Standard deviations are below 4%.
CrystEngComm, 2010, 12, 2343–2346 | 2345
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View Online[(Cy)4Ru4(Hoxonato)2(bpy)2](CF3SO3)4 species previously reported
by us.9 Remarkably, the activities of 1c, 2a–c do not significantly
diminish compared to the wild-type human ovarian cancer cells. This
means that they are apparently able to circumvent the acquired
resistance to cisplatin treatment.
In view of these results, it seems that the structural features
exhibited by the tetranuclear assemblies are optimal to exert a high
toxicity towards these cancer cell lines. Namely, the cationic and
hydrophobic/hydrophilic nature of these systems coupled to the
presence of highly extended aromatic phen ligands and redox active
OO,O0O0-exotetradentate organic spacers synergistically increases
their cytotoxic behaviour. In this regard, it should be remarked the
high performance of the 2c system which might be related to the
additional presence of extended aromaticity in the dhnq OO,O0O0-
exotetradentate ligand which might favour its non-covalent interac-
tion with polyanionic DNA. In relation to this, it should be noted the
unusual behaviour of the dimeric 1c compound, which also exhibits
very low IC50 values, as a probable consequence of its capacity to
intercalate DNA as envisaged from the competitive binding assays
with EB. On the other hand, in the case of 2a–c, their high activity as
anticancer drugs could be related to a combination of the activity of
the metallarectangles as vectors of the phen aromatic extended
systems. Finally, it should also be noted that the enhanced cytotox-
icity of the here reported systems compared to our previously
reported [(Cy)4Ru4(Hoxonato)2L2](CF3SO3)4 systems might also
correlate with the robustness of the later towards ligand exchange
reactions with cysteine.9
Conclusions
A series of redox active tetra cationic rectangular ruthenium open
boxes have been prepared and characterized by spectroscopic
methods, X-ray diffraction and cyclic voltammetry. In addition, we
have studied the ligand exchange reactions of these assemblies
towards bio-relevant S- and N-donor ligands, their interaction with
ct-DNA and screened for in vitro anticancer activity against cisplatin
sensitive ovarian carcinoma A2780 and cisplatin resistant A2780R
cancer cell line.
The results show that the dinuclear systems readily react with
S-donor cysteine and N-donor mononucleotides after ligand
exchange processes of the labile chloride ligands. At variance, the
tetranuclear assemblies only give ligand exchange reactions with
cysteine with the concomitant release of the exobidentate phen
ligands. On the other hand, the tetranuclear cationic assemblies
exhibit a significant higher cytotoxic activity and DNA binding
properties than their dinuclear precursors. Of particular interest is
their high antitumour activity towards A2780R cell line suggesting
the circumvention of resistance to a chemotherapeutic treatment. In
this regard, the reactivity of the tetranuclear species towards cysteine,
coupled to their redox activity and their ability to non-covalent
interact with the DNA double strand appears to synergistically
promote the increased cytotoxicity of these systems towards the
studied carcinoma.2346 | CrystEngComm, 2010, 12, 2343–2346Acknowledgements
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